Today Neurona announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) Designation for the company’s lead product candidate, NRTX-1001, which is being developed for drug-resistant mesial temporal lobe epilepsy (MTLE). The RMAT program is dedicated to advancing investigational regenerative medicines, including cell therapies, that are intended to treat, modify, reverse, or cure serious diseases where preliminary clinical evidence indicates that the regenerative medicine therapy has the potential to address unmet medical needs. Learn more about NRTX-1001 and this development in the press release here: https://lnkd.in/eJHzyZ6P #epilepsy #celltherapy
Fantastic news for Neurona Therapeutics and patients&families with epilepsy. Another exciting step for stem cell-derived therapies and a great example of rigorous science translating well into the clinic. Chapeau!
Wonderful news- right on the heels of BlueRock. Lovely to see this progress.
Congratulations Neurona team! I knew this was a game changing therapy when I was involved in writing the clinical study protocol!
Congratulations Neurona Therapeutics team! Fantastic news for people living with epilepsy and the field of PSC-derived cell therapies. All the best for the next steps!
Congratulations to the team at Neurona Therapeutics!
Congratulations Neurona Therapeutics team!
Congratulations! Wonderful news!
Congratulations, Neurona Team!!
Congrats to Neurona Therapeutics's team for this great achievement! Having seen patients testify last year how you changed their lives was really impressive and moving. Wishing a lot more patients will benefit from NRTX-1001!